KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Debt (2017 - 2019)

Xenon Pharmaceuticals (XENE) has disclosed Non-Current Debt for 3 consecutive years, with $10.9 million as the latest value for Q4 2019.

  • Quarterly Non-Current Debt changed N/A to $10.9 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $10.9 million through Dec 2019, changed N/A year-over-year, with the annual reading at $10.9 million for FY2019, N/A changed from the prior year.
  • Non-Current Debt for Q4 2019 was $10.9 million at Xenon Pharmaceuticals, down from $11.8 million in the prior quarter.
  • The five-year high for Non-Current Debt was $15.1 million in Q1 2019, with the low at $5.5 million in Q1 2018.
  • Average Non-Current Debt over 3 years is $11.2 million, with a median of $11.8 million recorded in 2018.
  • Peak annual rise in Non-Current Debt hit 176.46% in 2019, while the deepest fall reached 20.82% in 2019.
  • Over 3 years, Non-Current Debt stood at $6.1 million in 2017, then surged by 143.87% to $14.9 million in 2018, then decreased by 26.85% to $10.9 million in 2019.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $10.9 million, $11.8 million, and $13.2 million for Q4 2019, Q3 2019, and Q2 2019 respectively.